Mark W. Burket , MD

Country USA
Specialty Interventional Cardiologist
  1. Prognosis of the CLI patient - From Olive to Wifi
  2. The Modern Endovascular Approach to Infrapopliteal Occlusive Disease
  3. Where Are We Now? Current Scientific Evidences from Clinical Trials and Upcoming New Horizon
  4. DES vs. DCB: When to Choose?
  5. Cost Effectiveness of Endovascular Procedures - Can We Afford These Expensive Technologies?
  6. Next-Generation DCBs: "Make It Different?"
  7. Current and Upcoming Evidence-Based Approach in CLI: Endovascular vs. Surgery (OLIVE 3-Year and BEST-CLI Trial)
  8. Drug-Eluting Stents in the SFA(Zilver PTX or ELUVIA): Why Not Now? What Needed for the Future?
  9. Does Carotid Stent Cell Design Matter?: Open vs. Closed vs. Micromesh
  10. Zilver PTX 5-year Data: What Does It Mean to Clinical Practice?
  11. Percutaneous Reconstruction of Complex Aorto-Iliac Disease: Tips from Imaging to Intervention
  12. Customization of Carotid Revascularization Management to Optimize Outcomes
  13. Strong Supporter for Lumen Patency: Clear Long-term Efficacy of DES
  14. Proximal Protection Grabs the Initiative
  15. [Great Debate] Con: There Always Be a Need for Stenting for Femoropopliteal Lesion
  16. DES in Lower Extremity Intervention: Changed Landscape in the Current Practice ?
  17. Zilver PTX 2 Year Data
  18. Drug Eluting Stent Will Be Most Promising in Lower Limb Arterial Disease
  19. Drug-eluting Balloon or Stent in Femoropopliteal Lesions: How Far We Are ?
  20. The Drug Eluting Stent in the SFA
  21. Will Drug-coated Balloons, Drug-coated Stents Shift the Paradigm for Femoropopliteal Lesion
  22. Evolving Horizon: Drug-coated Balloons or Drug-coated Stents in SFA Diseases?
  23. Zilver PTX Randomized Trial of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: 24-Month Update